News
December 2023
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator, LEVI-04
November 2023
October 2022
First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients. Multiple arm, multi-centre, placebo-controlled study to evaluate five monthly infusions of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. ClinicalTrials.gov ID: NCT05618782
April 2022
Case Study interview with Simon Westbrook, CEO of Levicept in Bioprocess Online discussing his experience in selecting and working with a global CDMO partner, and the value Lonza brought to his virtual company.
https://www.bioprocessonline.com/doc/illustrating-a-successful-small-biotech-cdmo-relationship-0002
September 2021
Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.
March 2021
Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept. ClinicalTrials.gov ID: NCT03227796
February 2018
Interview with Simon Westbrook, CEO of Levicept in Labiotech by Alex Dale – This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis.
https://www.labiotech.eu/interview/osteoarthritis-pain-relief-levicept/
September 2014
Index Ventures, Advent Life Sciences and Gilde Healthcare invest £10 million Series A financing to develop LEVI-04 to proof-of-concept first-in-human clinical trials
April 2014
Innovate UK awards £2.4 million grant
February 2014
February 2014
Levicept is industrial SME in €5.9M PAINCAGE Consortium.
September 2013
Simon Westbrook acquires asset from Pfizer Ltd
March 2012
Index Ventures awards seed funding